Characteristics of Older Individuals with Asthma Being Treated with Biologics
Open Access
- 1 June 2025
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 18, 993-1002
Abstract
Purpose: Biologic (antibody) therapy is a safe, effective, and guideline-recommended treatment for patients with severe and otherwise uncontrolled asthma. The number of older individuals with asthma is increasing but there is a lack of data on the use of biologics in this cohort. Therefore, this study reports the characteristics of older individuals receiving biologic therapy for severe asthma. Patients and Methods: This study was a retrospective data analysis conducted at two centers in Germany. Results: Eighty-eight patients were included (52 aged 50– 59 years and 36 aged ≥ 60 years). There was a high rate of comorbidities and associated pharmacological therapy use. Nearly half (49%) of participants were current or ex-smokers and 29% had chronic obstructive pulmonary disease. The older age group (≥ 60 years) had significantly more cardiovascular comorbidities, more comorbidities overall, and a worse diffusion capacity compared with the group aged 50– 59 years. Baseline lung function parameters, and the change in lung function after 6 months of biologic therapy, did not differ significantly between the two age groups. Participants aged ≥ 60 years used self-injection less than those aged 50– 59 years. Conclusion: These data help to characterize the specific population of older people receiving biologic therapy for severe asthma, and showed a high rate of comorbidities, polypharmacy, and poor diffusion capacity in this group.Keywords
This publication has 25 references indexed in Scilit:
- Navigating biologic therapies in elderly asthmaRespiratory Medicine, 2024
- Tobacco Exposure and Efficacy of Biologic Therapy in Patients With Severe Asthma: A Nationwide Study From the Danish Severe Asthma RegisterThe Journal of Allergy and Clinical Immunology: In Practice, 2023
- Cellular senescence in asthma: from pathogenesis to therapeutic challengesEBioMedicine, 2023
- Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacyAllergology International, 2022
- MultimorbidityNature Reviews Disease Primers, 2022
- Advances in asthma: New understandings of asthma’s natural history, risk factors, underlying mechanisms, and clinical managementJournal of Allergy and Clinical Immunology, 2021
- Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015The Lancet Respiratory Medicine, 2017
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialThe Lancet, 2016
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- A Longitudinal, Population-Based, Cohort Study of Childhood Asthma Followed to AdulthoodNew England Journal of Medicine, 2003